CAH

Business Context and Reporting Period

Company: Cardinal Health, Inc. (formerly Cardinal Distribution, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended September 30, 1994 (First Quarter of Fiscal 1995)
Business Overview: The Company operates as a wholesale drug distributor. The reporting period reflects the retroactive effect of the pooling-of-interests merger with Whitmire Distribution Corporation (effective February 7, 1994) and includes the acquisition of Humiston-Keeling, Inc. (July 1, 1994) and Behrens Inc. (July 18, 1994).

Key Financial Metrics

Note: Q1 1994 figures are presented as reported in the filing; pro forma adjustments for the Whitmire merger are noted in the text but not restated in the primary table for direct comparison.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 41% year-over-year, driven by 30% internal growth (new customers, expanded territories, price increases) and contributions from recent acquisitions (Humiston-Keeling, Behrens, PRN Services).
• Margin Compression: Gross margin percentage declined to 5.68% from 6.02%. Management attributes this to lower selling margin rates due to a competitive market and a higher mix of volume customers, as well as reduced purchasing gains from lower drug price inflation.
• Operating Efficiency: Selling, general, and administrative (SG&A) expenses improved as a percentage of sales to 3.97% from 4.15%, benefiting from economies of scale and productivity improvements.
• Liquidity Position: Cash and equivalents increased by $71.8 million to $126.8 million. This was primarily funded by a $70 million public offering of common shares and an increase in accounts payable, offset by investments in receivables and inventory.
• Debt Reduction: The Company repaid $25 million in bank notes payable. Total long-term obligations remained relatively stable at approximately $211.5 million.

Outlook, Risks, and Unusual Items

• Guidance: Management expects the decline in gross margin rates to continue but at a more moderate pace. The Company believes it has adequate resources to meet capital expenditures and debt service requirements.
• Capital Markets: On September 26, 1994, the Company sold 1,867,000 new shares in a public offering, netting approximately $70 million for working capital. Additionally, $50 million of debt securities remain issuable under a prior registration statement.
• Legal Proceedings: The Company is a defendant in consolidated antitrust litigation ("Brand Name Prescription Drug Litigation") alleging price inflation via chargeback systems. A Judgment Sharing Agreement limits the Company's exposure to the lesser of 1% of any judgment or $1 million, with manufacturers agreeing to reimburse litigation costs up to $9 million. Management intends to contest the allegations vigorously.
• Acquisitions: The purchase of Humiston-Keeling was accounted for using the purchase method, while the Behrens combination was a pooling-of-interests. Neither acquisition significantly altered pro forma operating results for the period.

Investor Verification Checklist

• Margin Sustainability: Verify if the trend of declining gross margins (5.68%) stabilizes in subsequent quarters as management predicts.
• Working Capital Management: Monitor the continued growth in trade receivables ($473M) and inventory ($962M) to ensure they align with sales growth and do not signal collection or obsolescence issues.
• Legal Exposure: Track the status of the Brand Name Prescription Drug Litigation to confirm the $1 million liability cap remains effective.
• Debt Capacity: Confirm the utilization of the remaining $50 million debt issuance capacity and the status of the $315 million line-of-credit facility (currently unused).
• Share Count: Note the increase in outstanding shares due to the Whitmire merger, Behrens pooling, and the recent public offering, which may impact future earnings per share growth.